PolyPeptide Group Begins Large-Scale SPPS Production at Belgian Facility

• PolyPeptide Group AG has begun production at its €100M large-scale SPPS facility in Belgium.

PolyPeptide Group AG , a global CDMO specialising in peptide-based active pharmaceutical ingredients, has announced the commencement of production at its newly commissioned solid-phase peptide synthesis (SPPS) capacity in Braine-l’Alleud, Belgium. The €100 million facility represents the largest single investment in the company’s 70-year history.

Production follows the completion of construction and extensive testing, with a ramp-up scheduled through 2025. The new capacity will support a previously announced multi-year commercial agreement, which is expected to generate annual orders of approximately €100 million after the ramp-up phase.

The facility integrates PolyPeptide’s proprietary manufacturing technologies, advanced automation, and process controls. Its design incorporates closed material flows and reduced solvent consumption, improving sustainability and productivity. These advancements align with the company’s growth strategy and mid-term outlook shared in August 2024.

“This project is the largest single investment in PolyPeptide’s 70-year history,” said Juan José González, CEO of PolyPeptide. “The start of production is the result of the successful collaboration with our GLP-1 customer over several years. In parallel to the ramp-up ahead of us, we are pursuing our growth strategy with further GLP-1 capacity investments that combine innovative manufacturing technologies with the potential of modularity.”